Sprint Bioscience AB (SPRINT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared negative results for the last 2 consecutive quarters

The company has declared negative results in Sep 24 after 4 consecutive negative quarters
PRE-TAX PROFIT(Q) At SEK -5.64 MM has Fallen at -83.63%
NET PROFIT(Q) At SEK -5.64 MM has Fallen at -83.63%
RAW MATERIAL COST(Y) Grown by 53.83% (YoY)

Risky -

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 68 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.72

Return on Equity

-156.77%

Price to Book

4.75

Revenue and Profits:

Net Sales:

14 Million

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

165.0%

6 Months

283.13%

1 Year

-7.08%

2 Years

-13.08%

3 Years

153.43%

4 Years

-61.07%

5 Years

-74.94%

Sprint Bioscience AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

24.33%

EBIT Growth (5y)

7.54%

EBIT to Interest (avg)

-23.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.17

Sales to Capital Employed (avg)

4.31

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

7.10%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.37

EV to EBIT

-2.35

EV to EBITDA

-2.45

EV to Capital Employed

-5.04

EV to Sales

0.88

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-156.77%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -16.77% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -27.59% vs 50.43% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "13.90",
          "val2": "16.70",
          "chgp": "-16.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-5.40",
          "chgp": "-25.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-5.80",
          "chgp": "-27.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-507.90%",
          "val2": "-342.30%",
          "chgp": "-16.56%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 29.90% vs 50,400.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -4,475.00% vs 99.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65.60",
          "val2": "50.50",
          "chgp": "29.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.00",
          "val2": "-3.30",
          "chgp": "-475.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.30",
          "val2": "-0.40",
          "chgp": "-4,475.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-303.70%",
          "val2": "-73.90%",
          "chgp": "-22.98%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

13.90

16.70

-16.77%

Operating Profit (PBDIT) excl Other Income

-6.80

-5.40

-25.93%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.40

-5.80

-27.59%

Operating Profit Margin (Excl OI)

-507.90%

-342.30%

-16.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -16.77% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -27.59% vs 50.43% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

65.60

50.50

29.90%

Operating Profit (PBDIT) excl Other Income

-19.00

-3.30

-475.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-18.30

-0.40

-4,475.00%

Operating Profit Margin (Excl OI)

-303.70%

-73.90%

-22.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 29.90% vs 50,400.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -4,475.00% vs 99.34% in Dec 2023

All Annual Results

Company CV

About Sprint Bioscience AB

Sprint Bioscience AB

Pharmaceuticals & Biotechnology

Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Company Coordinates

Company Details

Novum, Halsovagen 7, Floor 8, elevator A , HUDDINGE None : 141 57

Tel: 46 8 4114455

https://www.sprintbioscience.com/

Registrar Details